REVB Revelation Biosciences
- 2.3700
- +0.0200+0.85%
- 2.3000
- -0.0700-2.95%
Revelation Biosciences News
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersAdial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwa
Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc.
Express News | Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 SAN DIEGO--(BUSINESS WIRE)--March 22, 2024-- Revelation Biosciences, Inc. (NASDAQ: RE
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
Solid Biosciences, Cue Biopharma, Annexon Among Healthcare Movers
Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration. It is being developed as a potential therapy for prevention and treatment o
Revelation Biosciences Showcases Research at Nephrology Conference
ETRN, CRDF and KC Are Among Pre Market Gainers
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications- Revelation Biosciences
OCGN, NEO and FRSX Are Among Pre Market Gainers
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Revelation Biosciences Secures $6.2M in Public Offering
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced
12 Health Care Stocks Moving In Monday's After-Market Session
GainersExicure (NASDAQ:XCUR) stock rose 70.0% to $0.94 during Monday's after-market session. The company's market cap stands at $8.0 million. Sharps Technology (NASDAQ:STSS) stock increased by 17.57%
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.97%
Top Midday Decliners
Revelation Biosciences (REVB) said Thursday that it has priced an offering of almost 1.37 million shares, together with warrants to purchase up to 2.73 million shares, targeting gross proceeds of abou
Analysis
Price Target
No Data
